Amarin (AMRN) Q2 2025 Earnings Transcript

Amarin reported Q2 2025 total net revenue of $72.7 million, up 8% year over year, driven mainly by a $26.1 million licensing/royalty contribution from the Recordati deal, while U.S. net product revenue fell 17% to $36.5 million on generic pricing pressure. Europe and Rest of World showed strong momentum, with European product revenue nearly doubling to $6.6 million and Rest of World product revenue rising to $3.5 million; South Korea also became Amarin’s 50th approved market. Management guided to about $70 million of annual operating expense savings from restructuring and said U.S. exclusives should support net pricing through year-end, but strategic alternatives remain open-ended.

Analysis

AMRN has effectively converted a deteriorating U.S. mature asset into a financing engine for a higher-quality royalty model. The key second-order effect is not the headline revenue mix shift, but that the Recordati handoff materially lowers the commercial intensity required to keep Europe growing, which should improve capital efficiency faster than the market likely expects over the next 2-4 quarters. If execution holds, the equity starts to trade less like a single-product U.S. erosion story and more like a cash-backed royalty platform with optionality from ex-U.S. markets.

The U.S. remains the swing factor near term, but the more important variable is not absolute revenue — it is how long exclusivity can be defended before the pricing ladder breaks again. A large payer moving back to exclusivity is a reminder that the business still has periodic step-function upside from formulary wins, but those gains are inherently fragile and can reverse quickly if rivals retaliate on price. That creates a narrow window where reported share can look better than the underlying category economics; investors should not extrapolate a single quarter of pricing stabilization into 2026 without evidence that the payer stack is durable.

The market is likely underappreciating how much the restructuring changes the runway: with a large fixed-cost reset, incremental ex-U.S. revenue should drop disproportionately to the bottom line once Recordati and the regional partners ramp. The contrarian risk is that Europe becomes a slower monetization curve than bulls expect because reimbursement/access is being translated into physician adoption, not yet into full sell-through. The setup is attractive, but this is still a patience trade — the bear case remains a sequence of small disappointments in ex-U.S. take-up plus another U.S. pricing reset, which would pressure both earnings and the strategic review narrative within 6-9 months.

Key Decisions for Investors

• Long AMRN on pullbacks for a 3-6 month catalyst window: thesis is cash-backed de-risking plus operating leverage from the $70M cost reset; risk/reward improves if the market underestimates how quickly royalty-like revenue can outpace lower fixed costs.
• Use a call spread in AMRN rather than outright stock if positioning for a Recordati-led rerating over the next 2 quarters; upside comes from multiple expansion on cleaner cash flow, while downside is capped by U.S. pricing noise.
• Pair trade: long AMRN / short higher-beta single-product commercialization names with heavier burn and weaker balance sheets over 6-12 months; AMRN now has the balance sheet to survive while many peers need flawless execution.
• Sell AMRN into any sharp rally if U.S. share ticks up on one-off payer wins without follow-through in net price stability; the core risk remains that a 2026 formulary reset re-prices the whole U.S. narrative lower.
• Monitor HLS.TO as a secondary beneficiary of Canadian access expansion; if reimbursement broadens as expected, HLS gets an incremental volume tailwind, but the trade is lower quality than AMRN because it is more exposed to launch cadence and reimbursement execution.